Literature DB >> 16115515

Neurohumoral pathways in heart failure with preserved systolic function.

Karen Hogg1, John McMurray.   

Abstract

Other than natriuretic peptides, neurohumoral markers have not been studied adequately in heart failure with preserved systolic function. There is little evidence of chronic activation of the renin-angiotensin-aldosterone and sympathetic nervous systems, as in heart failure with reduced systolic function. These and other neurohumoral pathways may, however, become excessively stimulated by exercise and during episodes of acute decompensation. Blood natriuretic peptide concentrations are chronically elevated in patients with heart failure and preserved systolic function but not to the same extent as in patients with reduced systolic function. The role of neurohumoral antagonists in the treatment of heart failure and preserved systolic function has yet to be fully investigated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16115515     DOI: 10.1016/j.pcad.2005.02.001

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  21 in total

1.  Heart failure with a normal ejection fraction: treatments for a complex syndrome?

Authors:  Samuel Bernard; Mathew S Maurer
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

Review 2.  Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: clinical perspectives.

Authors:  Fayez El Shear
Journal:  Am J Cardiovasc Dis       Date:  2019-10-15

Review 3.  Effect of renin-angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies.

Authors:  Hidekatsu Fukuta; Toshihiko Goto; Kazuaki Wakami; Nobuyuki Ohte
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

4.  Autonomic regulation device therapy in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Ahmed Bendary; Mohamed Bendary; Mohamed Salem
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

Review 5.  Impact of systemic venous congestion in heart failure.

Authors:  Matthias Dupont; Wilfried Mullens; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2011-12

Review 6.  Current perspectives on systemic hypertension in heart failure with preserved ejection fraction.

Authors:  A Afşin Oktay; Sanjiv J Shah
Journal:  Curr Cardiol Rep       Date:  2014-12       Impact factor: 2.931

Review 7.  The sympathetic nervous system and heart failure.

Authors:  David Y Zhang; Allen S Anderson
Journal:  Cardiol Clin       Date:  2014-02       Impact factor: 2.213

Review 8.  Hypertension and diastolic heart failure.

Authors:  Alan H Gradman; J Travis Wilson
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

Review 9.  Adrenergic nervous system in heart failure: pathophysiology and therapy.

Authors:  Anastasios Lymperopoulos; Giuseppe Rengo; Walter J Koch
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

10.  Characteristics of acute congestive heart failure with normal ejection fraction and less elevated B-type natriuretic peptide.

Authors:  Ken Shimamoto; Natsuha Koike; Kiyoko Mizuochi; Miho Honma; Yufuko Kasai; Akiko Sakai; Etsuko Fujita; Masatoshi Kawana
Journal:  BMC Cardiovasc Disord       Date:  2009-01-24       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.